



August 29, 2025

For Immediate Release

Company name: VITAL KSK HOLDINGS, INC.  
Representative: Taisuke Murai, President & CEO  
Company address: 1-1-12, Tsurumaki, Setagaya-ku, Tokyo  
(Securities Code: 3151, TSE Prime Market)  
Contact: Kenta Sato, Executive Officer,  
Manager of Corporate Planning Department  
(Tel. +81-3-5787-8565)

### **Notice Regarding Establishment of a Subsidiary**

VITAL KSK HOLDINGS, INC. (hereinafter "the Company") hereby announces that at the Board of Directors meeting held on August 29, 2025, it was resolved to establish a subsidiary and commence new pharmaceutical business operations through this subsidiary as detailed below.

#### **1. Purpose of Establishing the Subsidiary**

As announced in the "Notice of Conclusion of Exclusive License Agreement for the Development and Commercialization of Shield Therapeutics Plc's Iron Deficiency Treatment ACCRUFer® by Consolidated Subsidiary (VITAL-NET, INC.)" dated April 22, 2025, VITAL-NET, Inc., a wholly-owned subsidiary of the Company, entered into an exclusive license agreement (hereinafter "the Agreement") with Shield Therapeutics plc (London, UK, hereinafter "Shield") on April 18, 2025, for the exclusive development and marketing rights in Japan for ACCRUFer® (ferric maltol), Shield's main product. VITAL-NET, Inc. has initiated necessary activities to obtain manufacturing and marketing approval and commercialization of ACCRUFer® in Japan. The newly established subsidiary will succeed this Agreement and pursue manufacturing and marketing approval and commercialization of ACCRUFer®.

## 2. Overview of the Subsidiary

Company Name	Due to trademark application procedures, the company name will not be disclosed at this stage. It will be disclosed promptly after completion of trademark and related procedures.	
Representatives and Officers	President and Representative Director: Yuichi Kobayashi Director: Taisuke Murai Director: Takeshi Ichijo Director: Toshiyuki Iguchi Director: Mitsunao Suzuki Director: Hiroshi Yokoyama Auditor: Isao Kita	
Establishment	Late September 2025 (planned)	
Head Office Location	Due to ongoing registration procedures, the location cannot be disclosed at this time. It will be disclosed along with the company name upon completion of registration.	
Capital	100 million yen	
Shareholder Composition	Vital KSK Holdings, Inc. 100%	
Fiscal Year End	March 31	
Business Description	Research, development, manufacturing, and sales of pharmaceuticals	
Relationship between the Company and the New Subsidiary	Capital Relationship	The subsidiary will be 100% owned by the Company.
	Personnel Relationship	Yuichi Kobayashi, who will serve as President and Representative Director, is currently an Executive Officer of the Company. Additionally, directors of the Company are scheduled to serve concurrently as directors and auditors of the subsidiary. Furthermore, employees of the Company group are expected to hold concurrent positions in the subsidiary.
	Business Relationship	Not applicable as this is a newly established company.

## 3. Future Outlook

The impact of the establishment of this subsidiary on the consolidated financial results for the fiscal year ending March 2026 is expected to be minimal. The Company will promptly disclose any matters that should be announced as they become clear.